Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 63, Issue 21, Pages 2177-2187Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2014.01.050
Keywords
cardiovascular disease; heart disease; microRNA
Categories
Funding
- European Research Council [294609]
- Fondation LeDucq
- Fondazione CARIPLO [12-4-5157157-31]
- European Research Council (ERC) [294609] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Over the last few years, the field of microribonucleic acid (miRNA) in cardiovascular biology and disease has expanded at an incredible pace. miRNAs are themselves part of a larger family, that of non-coding RNAs, the importance of which for biological processes is starting to emerge. miRNAs are similar to 22-nucleotide-long RNA sequences that can legate messenger (m) RNAs at partially complementary binding sites, and hence regulate the rate of protein synthesis by altering the stability of the targeted mRNAs. In the cardiovascular system, miRNAs have been shown to be critical regulators of development and physiology. They control basic functions in virtually all cell types relevant to the cardiovascular system (such as endothelial cells, cardiac muscle, smooth muscle, inflammatory cells, and fibroblasts) and, thus, are directly involved in the pathophysiology of many cardiovascular diseases. As a result of their role in disease, they are being studied for exploitation in diagnostics, prognostics, and therapeutics. However, there are still significant obstacles that need to be overcome before they enter the clinical arena. We present here a review of the literature and outline the directions toward their use in the clinic. (C) 2014 by the American College of Cardiology Foundation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available